Hepatitis A Public Health Investigation Guidance

September 2021

Hepatitis A (HAV) is an acute, self-limiting viral illness associated with abrupt onset of fever, malaise, jaundice, anorexia, nausea, abdominal discomfort, and dark urine.

Development of clinical symptoms is highly age dependent. Among older children and adults, infection is typically symptomatic, and 70% present with jaundice. In children less than six years of age, 70% of infections are asymptomatic. Older persons and persons with chronic liver disease are more likely to have severe disease and HAV prevention in these groups is particularly important.

Definition of immunity
Persons are considered immune if they have:
- received 2 doses of HAV vaccine; or
- a history of IgM or total anti-HAV positivity during or up to four months after consistent clinical illness; or
- are IgG anti-HAV positive.

Post-vaccination serologic testing is not indicated because of the vaccine’s high efficacy. Most adults will be protected within 2-4 weeks after one dose of vaccine.

HAV vaccine was licensed in 1995 and has been routinely recommended for children in California and other high incidence states since 1999 and children in all states since 2005. Most California children/adolescents are immune.

Modes of transmission
HAV is very contagious. It is spread when someone unknowingly ingests fecal material—to through close personal or sexual contact with an infected person, through eating contaminated food or drink or through putting contaminated hands or objects in the mouth. HAV is present in blood and feces 10-12 days after infection. It is rarely transmitted by blood (e.g., via transfusion) or saliva.

Incubation period
The incubation period is 15-50 days, with a mean of 28 days.

Infectious period
Most immunocompetent adults shed virus in the stool and are infectious from 2 weeks before through 1 week after the onset of jaundice or elevation of liver enzymes, when concentration of virus in the stool is highest. In absence of jaundice, persons should be considered infectious for 2 weeks before through 1 week after the onset of hepatitis symptoms. Children may excrete virus longer than adults.

Clinical description
Acute illness with a discrete onset of any sign or symptom consistent with acute viral hepatitis (e.g., fever, headache, malaise, anorexia, nausea, vomiting, diarrhea, abdominal pain, or dark urine); AND
- jaundice or elevated total bilirubin levels >3.0 mg/dL; OR
- elevated serum alanine aminotransferase (ALT) levels >200 IU/L; AND
- the absence of a more likely diagnosis.

Laboratory criteria for diagnosis
- Immunoglobulin M (IgM) antibody to HAV (anti-HAV) positive; OR
- Nucleic acid amplification test (NAAT; such as
polymerase chain reaction (PCR) or genotyping for hepatitis A virus RNA.

Confirmed case definition

- A case that meets the clinical case criteria and is IgM positive*; OR
- has hepatitis A virus RNA detected by NAAT (such as PCR or genotyping); OR
- meets the clinical criteria and occurs in a person who had contact (e.g., household or sexual) with a laboratory-confirmed HAV case 15-50 days prior to onset of symptoms (epidemiologic linkage).

Criteria to distinguish a new case from an existing case

Hepatitis A infection is usually self-limiting and does not result in chronic infection. However, up to 10% of persons with hepatitis A may experience a relapse during the 6 months after acute illnesses. Cases of relapsing hepatitis A should not be enumerated as new cases.

Laboratory testing

IgM anti-HAV is present at the onset of illness. It usually disappears at <4 months but may persist >6 months. IgM anti-HAV is also occasionally detectable in adults 2 weeks after receiving HAV vaccine. IgG anti-HAV is detectable shortly after the appearance of IgM and is lifelong (Figure 1).

A positive IgM anti-HAV test result in a person without typical symptoms of HAV may indicate:

- a false-positive test result (this is common); or
- asymptomatic acute HAV infection; or
- previous HAV infection with persistent IgM.

Because of the risk of false positive results, IgM anti-HAV testing should be limited to persons with evidence of clinical hepatitis and should not be used as a screening tool or as part of testing panels in the workup of nonacute liver function abnormalities.

Public health actions such as postexposure prophylaxis should generally not be undertaken in situations where the clinical criteria of the case definition are not met. In situations of high concern where a positive HAV IgM is received but the clinical criteria are not met, repeat IgM anti-HAV testing and/or HAV PCR testing at the CDPH VRDL may be helpful for public health decision-making.

Hepatitis A PCR testing and genotyping

The CDPH VRDL can perform HAV PCR testing and genotyping. Please submit specimens to VRDL for PCR and genotyping for case-patients who meet the case definition and who are injection/non-injection drug users, experiencing homelessness, MSM, or have no known HAV risk factor.

Specimens can be submitted using the VRDL General Purpose Specimen Submittal Form. Please see CDPH HAV testing guidance for additional information.

Hepatitis A postexposure prophylaxis (PEP)

All nonimmune people who are exposed to hepatitis A virus (HAV) and have not been previously infected or vaccinated should receive PEP within 14 days after the date of last exposure. PEP should be given as soon as possible during the appropriate time window. See CDPH HAV PEP guidance for more information.

Routine Immunization

The 2-dose HAV vaccine series is routinely
recommended for children 12 months through 18 years of age and for persons at increased risk of HAV infection. These persons include travelers to endemic areas, MSM, injection/non-injection drug users, persons with chronic liver disease or clotting factor disorders, persons experiencing homelessness and persons living with HIV. There is no routine recommendation for HAV vaccination of food handlers or healthcare workers.

Pre-exposure prophylaxis (international travel)
Susceptible persons traveling to countries with high or intermediate HAV endemicity (See a list of regions where Hepatitis A is endemic) should be vaccinated or receive intramuscular immune globulin (IMIG) (0.1 mL/kg) before travel. A first dose of single-antigen HAV vaccine given up to the date of departure should protect most healthy persons.

In addition to HAV vaccine, IG may be considered before travel for persons with increased risk for complications in the event of HAV infection, such as immunocompromised people and people with liver disease. IG may also be considered in addition to vaccine for people >40 years of age based on the provider’s risk assessment.

Infants aged 6-11 months should receive HAV vaccine before travel to high or intermediate HAV endemic countries, but the dose should not be counted towards the routine 2-dose series. Infants <6 months of age, and those for whom vaccine is contraindicated, should receive IG. IG dosing varies by duration of travel. See CDC hepatitis A prophylaxis guidance for specifics.

Combined HAV/HBV vaccine “accelerated” schedule
The first 2 doses of the combined HAV/HBV vaccine (Twinrix®) accelerated schedule provide equivalent protection to the first dose in the standard, single-antigen adult HAV vaccine 2-dose series and the first 2 doses in the standard adult HBV vaccine series. Therefore, this schedule offers no particular benefit and CDC recommends the regular schedule when possible.

Close contact definition

Household/sexual contacts, drug sharers, childcare center staff/attendees, and others with ongoing close contact.

Risk for HAV transmission in different settings
HAV transmission risk varies by setting. Household secondary attack rates are 15-30%; higher rates of transmission are associated with infected children.

In contrast, attack rates are low among restaurant patrons who have been exposed to infected food handlers.

Food service settings
HAV-infected food handlers should be excluded for 1 week after jaundice onset (or if no jaundice, during peak aminotransferase activity or for one week after symptom onset). Other potentially exposed food handlers in the same setting should be offered PEP.

Because transmission to patrons is unlikely, PEP is not routinely indicated for patrons, but may be considered if, while infectious, the food handler:

- directly handled (without gloves) uncooked or cooked foods or beverages; and
- had diarrhea or poor hygienic practices† at work; and
- patrons can be identified and treated no later than 2 weeks after exposure (see Figure 2 algorithm on page 5).

Note: If repeated exposures might have occurred (e.g., in an institutional cafeteria), stronger consideration of PEP for patrons may be warranted.

In a common source outbreak, PEP is not indicated for exposed persons after cases have begun to occur, because the 2-week period during which PEP is known to be effective will have been exceeded. If a common source is suspected in 2 or more cases, the CDC Hepatitis Reference Laboratory can perform molecular typing. Contact CDPH at 510-620-3737 for more information.
**Healthcare settings**

PEP is not routinely indicated for staff who have provided care for an HAV-infected patient. When providing care for HAV-infected patients, contact precautions are recommended (in addition to standard precautions) for diapered and incontinent patients for at least 1 week after symptom onset.

PEP is indicated for persons who have had close contact with HAV cases if an epidemiological investigation indicates that HAV transmission has occurred among patients or between patients and staff.

**Childcare settings**

Exclude HAV-infected childcare staff and attendees for 1 week after onset of jaundice (or if no jaundice, onset of symptoms. If asymptomatic, use time of peak ALT/AST).

PEP is indicated for previously unvaccinated staff/attendees if a case of HAV is diagnosed in staff/attendees or if HAV cases are diagnosed in 2 or more households of attendees. Because infections in children usually are mild or asymptomatic, clusters in daycares often are identified only when adult contacts (e.g. parents) become ill.

**Schools and other work settings**

PEP is not routinely indicated when a single HAV case occurs in elementary or secondary schools or work settings other than those specified above.

PEP is indicated for persons who have close contact with cases if an epidemiological investigation indicates that transmission has occurred among students at a school.
Figure 2: Algorithm Used by New York City Department of Health and Mental Hygiene to Determine the Need for Hepatitis A Virus Postexposure Prophylaxis of Restaurant Patrons‡.

- Probable low risk
- Individual evaluation required
- Provide postexposure prophylaxis to other kitchen and restaurant employees

- Probable low risk
- Individual evaluation required
- Give postexposure prophylaxis to other kitchen and restaurant employees

- No further action

- No postexposure prophylaxis

- No postexposure prophylaxis
And is not otherwise ruled out by PCR testing for hepatitis A virus performed in a public health laboratory.

Hygiene assessments are subjective; a visit to the food handling area and interviews with the infected food handler, coworkers, and supervisors are often helpful. Additional factors include availability of hand washing facilities, hygiene training, previous assessments of sanitation practices in the facility, and the presence of medical conditions in the infected food handler that might make hygiene more difficult to maintain.